Search

everythinglearnresearchcommunity

for

Search:↓

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

3D imaging effectively tracks skin changes in vitiligo treatment.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

The document did not conclude on apremilast's effectiveness for severe alopecia areata.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Certain drugs may cause vitiligo, so patients should be monitored.

More research is needed to find the best treatment for dissecting cellulitis of the scalp.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.

Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.

Ongoing research and innovation are crucial for improving skin care and treatment.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

Secukinumab can cause hair loss, which may improve after stopping the medication.

IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.

Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.

Fumaric acid esters, especially dimethylfumarate, improve psoriasis treatment.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Talquetamab may cause hair loss and skin issues.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Upadacitinib may effectively treat resistant lichen planopilaris.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.